+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
ID07719491

Evaluating Safety and Pharmacokinetics of GS-0415 in Adults with Suppressed HIV-1 on Antiretroviral Therapy in a Single-Blind, Placebo-Controlled Dose Escalation Study

Led by Gilead Sciences · Updated on 2026-09-23

112

Participants Needed

16

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the drug GS-0415 to learn about its safety, tolerability, and how it behaves in the body in people living with HIV-1 who are already on antiretroviral therapy and have their virus suppressed. This Phase 1b clinical trial focuses on testing single and multiple escalating doses given either under the skin or through a vein, evaluating side effects and drug levels in the blood. Participants are randomly assigned to receive either GS-0415 or a matching placebo. The study includes groups receiving single ascending doses on Day 1 and groups receiving multiple ascending doses at up to five timepoints until Day 57. The drug and placebo are administered via subcutaneous injection or intravenous infusion. The trial uses a single-blind design, meaning participants do not know which treatment they receive. During the study, participants will be monitored for side effects, laboratory abnormalities, and drug levels in the blood up to 99 days after dosing. Researchers will also check for immune responses to the drug and any return of the virus. The study involves regular assessments and safety monitoring to understand how GS-0415 is processed and tolerated over time, with the overall participation lasting several months.

CONDITIONS

Brief Title

Study of GS-0415 and How It Works in People With HIV

Research Team

G

Gilead Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here